AlphaMed Pharmaceuticals Corporation

AlphaMed Pharmaceuticals Announces Breakthrough in the Development of Recombinant Alpha 1-Antitrypsin

Published in Lab Business Week, March 23rd, 2008

AlphaMed Pharmaceuticals Corporation announced that the Company has successfully expressed a humanized version of the therapeutic protein alpha 1-antitrypsin (AAT). AlphaMed scientists expressed their recombinant AAT utilizing the Company's proprietary production system in yeast. The yeast has been genetically altered to produce a molecule "virtually identical" to that which is manufactured by the human body.

"This marks a major milestone for this company and AAT research," stated Joseph McGuirl, AlphaMed's CEO, "AlphaMed is the first company to develop an AAT molecule with glycosylation that resembles the human protein that is naturally secreted from the liver. The...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Lab Business Week

Source: Lab Business Week (2008-03-23)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry